VIEW PDF VERSIONGuidance Category
Module 3: Tests for tuberculosis infection
Module 3: Tests for tuberculosis infection
Table of Content (Online Version) :
- Acknowledgements
- Abbreviations and acronyms
- 1. Introduction
-
2. Testing for TB infection and a model algorithm
- 2.1 Who should be tested for TB infection?
- 2.2 Risk of disease in those with positive tests for TB infection
- 2.3 What are the advantages and disadvantages of testing for TB infection?
-
2.4 When is TB infection testing not advised?
- 2.4.1 Prior positive TB infection tests
- 2.4.2 Concomitant or recent vaccines or viral illnesses
- 2.4.3 Clinical work-up of adults to diagnose TB disease or monitoring of the response to treatment
- 2.4.4 History of TST or TBST allergic reactions (but IGRAs may be used)
- 2.4.5 Challenges with blood collection in young children when using IGRAs (but TBST may be used)
- 2.5 An integrated and person-centred model algorithm
- 3. WHO-recommended tests for TB infection
-
4. Programmatic considerations for implementing TB infection tests
- 4.1 General considerations: integrated and person-centred TB infection cascade of care
-
4.2 Steps for programmatic implementation of testing for TB infection
- 4.2.1 Area 1 – Policies, budgeting and planning
- 4.2.2 Area 2 – Regulatory approval and importation of products
- 4.2.3 Area 3 – Equipment and materials
- 4.2.4 Area 4 – Human resource sensitization, training and competency assessment
- 4.2.5 Area 5 – Supply chain
- 4.2.6 Area 6 – Procedures
- 4.2.7 Area 7 – Digital data
- 4.2.8 Area 8 – QA, QC and quality assessment
- 4.2.9 Area 9 – Recording and reporting
- 4.2.10 Area 10 – Monitoring and evaluation
- References
- Annex 1. Skin tests for tuberculosis infection – detailed description
- Annex 2. Interferon-gamma release assays – detailed description